Patent ID: 8778013

Claim:
A drug-delivering insertable medical device comprising a stent for treating a medical condition associated with a body lumen comprising an artery, the artery comprising a plurality of layers, the drug-delivering insertable medical device comprising: an outer surface coated with a plurality of nano-carriers having a first average diameter, a second average diameter, and a third average diagmeter; a nano-carrier of the plurality of nano-carriers comprising a sirolimus drug surrounded by an encapsulating medium, the encapsulating medium comprising at least one of a biological agent, a blood excipient, and a phospholipid, the nano-carrier having an average diameter suitable for penetrating at least one layer of the plurality of layers and a surface of the nano-carrier being devoid of the drug; a first set of the nano-carriers having a first average diameter ranging from 800 nm to 1500 nm suitable for penetrating an intima layer of the artery through inter-tissue pores present in the intima layer, a second set of nano-carriers having a second average diameter ranging from 300 nm to 800 nm suitable for penetrating a media layer of the artery through a vasa vasorum associated with the media layer and the inter-tissue pores present in the intima layer, and a third set of nano-carriers having a third diameter ranging from 10 nm to 300 nm suitable for penetrating an adventitia layer of the artery through the inter-tissue pores present in the intima layer, the vasa vasorum associated with the media layer and a vasa vasorum associated with the adventitia layer; wherein the third set of nano-carriers penetrating into the adventitia layer remain in the adventitia layer for a prolonged time and acts as a reservoir of the sirolimus drug to slowly release the sirolimus drug over a prolonged time; wherein the sirolimus drug diffuses across the adventitia layer, the media layer and the intima layer during the prolonged time to provide an in-tissue diffusion of the drug for the prolonged time to supply a maximum portion of a lesion of the artery with the sirolimus drug; and wherein the prolonged time comprises 39 days.